Holen Sie sich die Stockscreener-App
8.40
0.94%
-0.08
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Neil F. McFarlane, Zevra Therapeutics president, sells $125k in shares - Investing.com Canada
Stock Analysis: What is the implied volatility of Zevra Therapeutics IncEarnings Growth Report & Technical Confirmation Alerts - baoquankhu1.vn
Zevra Therapeutics opens Nasdaq with bell ceremony - Traders Union
Zevra Therapeutics Rings the Opening Bell - Nasdaq
Will Zevra Therapeutics Inc. benefit from geopolitical trendsWeekly Profit Analysis & Expert Approved Momentum Ideas - mfd.ru
Responsive Playbooks and the ZVRA Inflection - Stock Traders Daily
Zevra Therapeutics, Inc. (ZVRA) Investor Outlook: Unpacking a 169.66% Potential Upside with Robust Revenue Growth - DirectorsTalk Interviews
Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C at the 22nd Annual WorthLDSymposium - marketscreener.com
ZVRA: Zevra Therapeutics Unveils Promising Data on Miplyffa at W - GuruFocus
Zevra Therapeutics Presents Positive Data on MIPLYFFA® for Niemann-Pick Disease Type C at WORLDSymposium™ 2026 - Quiver Quantitative
4 years of real-world data track MIPLYFFA in rare Niemann-Pick disease - Stock Titan
Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock By Investing.com - Investing.com Australia
Schafer Joshua, CCO of Zevra, sells $29,800 in ZVRA stock - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $29,801.25 in Stock - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Insider Sells $40,026.39 in Stock - MarketBeat
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock - MarketBeat
Insider Selling: Zevra Therapeutics (NASDAQ:ZVRA) SVP Sells 1,750 Shares of Stock - MarketBeat
Zevra Therapeutics CEO McFarlane sells $853k in shares By Investing.com - Investing.com South Africa
Zevra Therapeutics CEO McFarlane sells $853k in shares - Investing.com
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 - The Manila Times
Published on: 2026-02-02 12:45:20 - baoquankhu1.vn
Portfolio Shifts: Can Zevra Therapeutics Inc maintain sales growthJuly 2025 Spike Watch & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Layoff Watch: Does Zevra Therapeutics Inc have declining or rising EPS2025 Growth vs Value & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January - MarketBeat
Is Zevra Therapeutics Inc. forming bullish engulfing patternsMarket Movement Recap & Expert Verified Stock Movement Alerts - mfd.ru
Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Exploring a Promising 154% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Understanding the Setup: (ZVRA) and Scalable Risk - Stock Traders Daily
Delaware Chancery Court Ruling Finds a Security Interest is a “Transfer” – Commave v. Zevra - The National Law Review
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™ - GlobeNewswire
Investing in Zevra Therapeutics (NASDAQ:ZVRA) three years ago would have delivered you a 63% gain - Yahoo Finance
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% HigherHere's What Happened - MarketBeat
ZVRA Stock Price and Chart — NASDAQ:ZVRA - TradingView
Insider Buy: What is Zevra Therapeutics Incs market positionJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
Volume Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsEarnings Risk Report & Low Risk Growth Stock Ideas - baoquankhu1.vn
The Technical Signals Behind (ZVRA) That Institutions Follow - Stock Traders Daily
Published on: 2026-01-17 12:49:06 - baoquankhu1.vn
J.P. Morgan: Zevra Sees EU As Land Of Opportunity For Miplyffa - Citeline News & Insights
Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C - MSN
Is Zevra Therapeutics (ZVRA) Using J.P. Morgan Spotlight To Reframe Its Rare-Disease Investment Story? - simplywall.st
Zevra Therapeutics (ZVRA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Zevra Therapeutics Reports Strong Q3 Earnings and Strategic Growth - MSN
Zevra Therapeutics FY 2024 Earnings Preview - MSN
Can Zevra Therapeutics Inc. stock withstand economic slowdownJuly 2025 Sentiment & Verified Entry Point Signals - Улправда
How Zevra Therapeutics Inc. stock benefits from tech adoptionJuly 2025 Rallies & Expert Approved Trade Ideas - ulpravda.ru
Can Zevra Therapeutics Inc. stock double in next 5 yearsJuly 2025 Gainers & Reliable Volume Spike Alerts - Улправда
Can Zevra Therapeutics Inc. stock sustain revenue growthTrade Performance Summary & Stock Market Timing Techniques - ulpravda.ru
Is Zevra Therapeutics Inc. stock a top pick in earnings season2025 Risk Factors & Fast Gain Swing Alerts - Улправда
Will Zevra Therapeutics Inc. stock deliver strong dividend growthWeekly Gains Report & Verified Momentum Stock Ideas - ulpravda.ru
What Wall Street predicts for Zevra Therapeutics Inc. stock priceAnalyst Downgrade & Precise Entry and Exit Recommendations - Улправда
Is Zevra Therapeutics Inc. stock a buy before product launchesWeekly Gains Summary & Weekly Stock Performance Updates - Улправда
Aug EndMonth: How Zevra Therapeutics Inc. (1GDA) stock reacts to fiscal policies2025 Price Targets & Accurate Entry and Exit Point Alerts - ulpravda.ru
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):